The clinical efficacy of Rituximab administration in autoimmunity disorders, primary immunodeficiency diseases and malignancies

Zian, Zeineb; Berry, S.P. Déo-Gracias; Bahmaie, Nazila; Ghotbi, Dana; Ali, Kawsar; Madkaikar, Manisha; Bargir, Umair Ahmed; Abdullahi, Hamisu; Khan, Haroon; Azizi, Gholamreza

doi:10.1016/j.intimp.2021.107565

Cited by 7 publications

(10 citation statements)

References 136 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The dosage of aminophylline described in previous reports that used aminophylline for the treatment of methotrexate-induced neurotoxicity in chemotherapy for acute lymphoblastic leukemia and pineoblastoma, was 2.5 mg/kg or 145 mg; this is relatively lower compared with the dosage described in this case report (12 mg/kg). 1,3,7,8 In addition, other case reports have suggested that intravenous aminophylline (100 mg every 6 hours) used for the treatment of methotrexate-induced neurotoxicity improved the symptoms. 6 However, treatment using aminophylline was ceased because of tachycardia and agitation as side effects of theophylline overdoses.…”

Section: Dosage Of Aminophylline Used For the Treatment Of Neurotoxic...mentioning

confidence: 97%

“…To the Editor: I read the interesting case report entitled "High-Dose Aminophylline for Methotrexate-Induced Neurotoxicity in a Patient With Brain Metastasis," recently published in the American Journal of Therapeutics. 1 Methotrexate is an antifolate antimetabolite, which is used in chemotherapy for cancer and immunosuppression for autoimmune diseases. 2 The underlying mechanism of methotrexate involves the inhibition of dihydrofolate reductase, which is involved in the conversion of dihydrofolate to tetrahydrofolate, leading to the inhibition of nucleotide synthesis in deoxyribonucleic and ribonucleic acid.…”

Section: Dosage Of Aminophylline Used For the Treatment Of Neurotoxic...mentioning

confidence: 99%

“…Rituximab is a monoclonal antibody–based immunotherapy targeting CD20 ligand on B cells, which has been proven effective against immune-mediated diseases. 1 The CD20 receptor is expressed on B cells, and rituximab forms a cap once it binds to B cells. Natural killer cells latch onto to the cap and cause apoptosis of the cell.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Successful Treatment of Sjogren-Associated Interstitial Lung Disease With Rituximab

Kesireddy

Khokher

Chuang

et al. 2021

American Journal of Therapeutics

View full text Add to dashboard Cite

Section: Dosage Of Aminophylline Used For the Treatment Of Neurotoxic...mentioning

confidence: 97%

Section: Dosage Of Aminophylline Used For the Treatment Of Neurotoxic...mentioning

confidence: 99%

See 1 more Smart Citation

Successful Treatment of Sjogren-Associated Interstitial Lung Disease With Rituximab

Kesireddy

Khokher

Chuang

et al. 2021

American Journal of Therapeutics

View full text Add to dashboard Cite

“…Antibodies represent a powerful means for the treatment of immune diseases because they can target ligands or receptors involved in the abnormal amplification of molecular signals responsible for the symptoms. Currently, there are antibodies approved for treating autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease, type 1 diabetes, psoriasis, lupus, and multiple sclerosis ( 114 ). Even though this implies the necessity of more frequent treatments, antibody fragments with short half-life period are considered safer because of their reduced retention time and their engineering into dual-target reagents provides the advantage of blocking pairs of inflammatory cytokines at the same time, increasing the treatment efficacy ( 7 ) ( Table 3 ).…”

Section: Nanobody Applications For Autoimmune Diseasesmentioning

confidence: 99%

Research Progress and Applications of Multivalent, Multispecific and Modified Nanobodies for Disease Treatment

et al. 2022

View full text Add to dashboard Cite

Recombinant antibodies such as nanobodies are progressively demonstrating to be a valid alternative to conventional monoclonal antibodies also for clinical applications. Furthermore, they do not solely represent a substitute for monoclonal antibodies but their unique features allow expanding the applications of biotherapeutics and changes the pattern of disease treatment. Nanobodies possess the double advantage of being small and simple to engineer. This combination has promoted extremely diversified approaches to design nanobody-based constructs suitable for particular applications. Both the format geometry possibilities and the functionalization strategies have been widely explored to provide macromolecules with better efficacy with respect to single nanobodies or their combination. Nanobody multimers and nanobody-derived reagents were developed to image and contrast several cancer diseases and have shown their effectiveness in animal models. Their capacity to block more independent signaling pathways simultaneously is considered a critical advantage to avoid tumor resistance, whereas the mass of these multimeric compounds still remains significantly smaller than that of an IgG, enabling deeper penetration in solid tumors. When applied to CAR-T cell therapy, nanobodies can effectively improve the specificity by targeting multiple epitopes and consequently reduce the side effects. This represents a great potential in treating malignant lymphomas, acute myeloid leukemia, acute lymphoblastic leukemia, multiple myeloma and solid tumors. Apart from cancer treatment, multispecific drugs and imaging reagents built with nanobody blocks have demonstrated their value also for detecting and tackling neurodegenerative, autoimmune, metabolic, and infectious diseases and as antidotes for toxins. In particular, multi-paratopic nanobody-based constructs have been developed recently as drugs for passive immunization against SARS-CoV-2 with the goal of impairing variant survival due to resistance to antibodies targeting single epitopes. Given the enormous research activity in the field, it can be expected that more and more multimeric nanobody molecules will undergo late clinical trials in the next future.Systematic Review Registration

show abstract

“…Rituximab is a chimeric mouse/human monoclonal antibody directed against the CD20 antigen present on the surface of mature B cells and on >90% of mature B-cell NHL [45][46][47][48][49]. In adults, rituximab in its originator and various biosimilar forms is indicated for the treatment of NHL, CLL, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis, and pemphigus vulgaris [21,22].…”

Section: Rituximabmentioning

confidence: 99%

Secondary Dysgammaglobulinemia in Children with Hematological Malignancies Treated with Targeted Therapies

Tragiannidis

Groll

2021

Pediatr Drugs

View full text Add to dashboard Cite

Targeted therapies have emerged as innovative treatments for patients whose disease does not respond to conventional chemotherapy, and their use has widely expanded in the field of pediatric hematologic malignancies in the last decade. While they carry the promise of improved disease control and survival and are currently investigated in first-line treatment protocols for patients with poor prognostic markers, they are associated with a considerable incidence of specific toxicities, including cytokine-release syndrome, neurotoxicity, hepatotoxicity, nephrotoxicity, cardiotoxicity, endocrine adverse events, and infectious complications. Iatrogenic or secondary dysgammaglobulinemia is a main consequence of targeted therapies using monoclonal antibodies and other antibody-derived treatments that target specific antigens on lymphoid cells (blinatumomab, inotuzumab ozogamicin, rituximab), chimeric antigen receptor T cells, tyrosine kinase inhibitors (imatinib, dasatinib, nilotinib) and, to a lesser extent, checkpoint inhibitors (pembrolizumab, nivolumab). This review discusses the diagnosis and incidence of secondary or iatrogenic dysgammaglobulinemia in children treated with targeted therapies for leukemias and lymphomas, and options for monitoring and treatment.

show abstract

The clinical efficacy of Rituximab administration in autoimmunity disorders, primary immunodeficiency diseases and malignancies

Cited by 7 publications

References 136 publications

Successful Treatment of Sjogren-Associated Interstitial Lung Disease With Rituximab

Successful Treatment of Sjogren-Associated Interstitial Lung Disease With Rituximab

Research Progress and Applications of Multivalent, Multispecific and Modified Nanobodies for Disease Treatment

Secondary Dysgammaglobulinemia in Children with Hematological Malignancies Treated with Targeted Therapies

Contact Info

Product

Resources

About